1. Home
  2. PT vs SABS Comparison

PT vs SABS Comparison

Compare PT & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PT
  • SABS
  • Stock Information
  • Founded
  • PT 2012
  • SABS 2014
  • Country
  • PT China
  • SABS United States
  • Employees
  • PT N/A
  • SABS N/A
  • Industry
  • PT Computer Software: Programming Data Processing
  • SABS Biotechnology: Pharmaceutical Preparations
  • Sector
  • PT Technology
  • SABS Health Care
  • Exchange
  • PT Nasdaq
  • SABS Nasdaq
  • Market Cap
  • PT 15.2M
  • SABS 15.8M
  • IPO Year
  • PT 2018
  • SABS N/A
  • Fundamental
  • Price
  • PT $0.95
  • SABS $2.28
  • Analyst Decision
  • PT
  • SABS Strong Buy
  • Analyst Count
  • PT 0
  • SABS 5
  • Target Price
  • PT N/A
  • SABS $10.00
  • AVG Volume (30 Days)
  • PT 5.2K
  • SABS 85.9K
  • Earning Date
  • PT 11-07-2025
  • SABS 11-05-2025
  • Dividend Yield
  • PT N/A
  • SABS N/A
  • EPS Growth
  • PT N/A
  • SABS N/A
  • EPS
  • PT N/A
  • SABS N/A
  • Revenue
  • PT $4,814,566.00
  • SABS $114,698.00
  • Revenue This Year
  • PT N/A
  • SABS N/A
  • Revenue Next Year
  • PT N/A
  • SABS N/A
  • P/E Ratio
  • PT N/A
  • SABS N/A
  • Revenue Growth
  • PT N/A
  • SABS N/A
  • 52 Week Low
  • PT $0.76
  • SABS $1.00
  • 52 Week High
  • PT $1.15
  • SABS $6.60
  • Technical
  • Relative Strength Index (RSI)
  • PT 48.66
  • SABS 54.42
  • Support Level
  • PT $0.98
  • SABS $2.03
  • Resistance Level
  • PT $0.98
  • SABS $2.34
  • Average True Range (ATR)
  • PT 0.03
  • SABS 0.12
  • MACD
  • PT -0.00
  • SABS 0.02
  • Stochastic Oscillator
  • PT 18.18
  • SABS 84.00

About PT Pintec Technology Holdings Limited

Pintec Technology Holdings Ltd is a technology platform that provides financial services in China in terms of loan volume facilitated. The company connects business partners and financial partners on its open platform and enables them to provide financial services to end-users. Its products include installment loans, personal loans, wealth management, insurance brokerage, SME loans, and others. The company generates its revenue from technical service fees, as well as by providing financing for these borrowers and earning installment service fees. The company earns wealth management services fees and commissions on financial products. The company generates the majority of its revenue from Wealth management service fees and others.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Share on Social Networks: